证券代码：600873 证券简称：梅花生物 公告编号：2025-049 梅花生物科技集团股份有限公司 关于2025年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条相关规定， 现将梅花生物科技集团股份有限公司（以下简称"公司"）2025 年半年度经营 数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 356,622.56 | | 饲料氨基酸（赖氨酸、苏氨酸、饲料级缬氨酸等） | 565,978.16 | | 医药氨基酸（谷氨酰胺、脯氨酸、异亮氨酸、鸟苷、腺苷等） | 24,734.04 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 188,930.22 | | 其他（黄原胶、海藻糖等） | 91,780.08 | | 合计 | 1,228,045.06 | 2、按销售模式分： 特此公告。 梅花生物科技集团股份有限公司董事会 ...

Core Viewpoint - The company achieved a net profit of 1.142 billion yuan after deducting non-recurring items in 2024, representing a year-on-year increase of 57.07%, primarily due to a significant increase in product sales [1][3]. Financial Performance - The company reported an operating income of 17.334 billion yuan in 2024, a slight decrease of 0.23% year-on-year. The net profit attributable to shareholders was 943 million yuan, up 39.12% year-on-year, while the net profit after deducting non-recurring items was 1.142 billion yuan, reflecting a 57.07% increase [3]. - For Q1 2025, the company achieved a total operating income of 4.039 billion yuan, a decrease of 3.82% year-on-year, but the net profit after deducting non-recurring items was 462 million yuan, showing an impressive year-on-year growth of 81.61% [4]. Dividend Distribution - The company plans to distribute a cash dividend of 0.38 yuan per share (before tax), with an estimated total cash dividend of approximately 631.36 million yuan (before tax), accounting for 66.94% of the net profit attributable to shareholders [3]. Future Profit Forecast - The company forecasts net profits attributable to shareholders for 2025, 2026, and 2027 to be 1.318 billion yuan, 1.433 billion yuan, and 1.601 billion yuan, respectively, with corresponding EPS of 0.79, 0.86, and 0.96 yuan [2]. Project Development - The company is accelerating the construction of a 600,000-ton corn deep processing and supporting cogeneration project, aiming for trial production by the end of 2025, with a total investment of approximately 3.712 billion yuan [4]. - The company is also steadily advancing the nucleotides technical transformation project in Zhaodong, with an investment of 167.29 million yuan, expected to take 16 months [4].